Literature DB >> 12607601

p53 protein and Ki-67 overexpression in urothelial dysplasia of bladder.

Wei Sun1, Ping L Zhang, Guillermo A Herrera.   

Abstract

Mutated tumor suppression gene p53 is a common genetic abnormality in most papillary or invasive transitional cell carcinomas (TCC). In these cases, overexpression of p53 protein is detectable in nuclei by immunohistochemical methods. Nuclear antigen Ki-67, a marker of cellular proliferation, has been shown to correlate with the growth of many human neoplasms, including TCC. Since overexpression of p53 protein and increased Ki-67 proliferative activity have been a consistent finding in TCC, p53 and Ki-67 expression may be used as markers of urothelial cells with significant genetic alterations. In this study, the authors have investigated whether there is increased p53 and Ki-67 expression in varying grades of urothelial dysplasia. Staining for p53 and Ki-67 using formalin-fixed, paraffin-embedded sections was performed using a Dako Autostainer, followed by counting positive cells using an automatic cellular imaging system (ACIS). The high-grade dysplasia/CIS group (n = 16) had a similar high percentage and intensity of p53 staining (45.3 +/- 4.3%; 28.2 +/- 6.1 arbitrary units [AU]) as the TCC group (n = 16. 53.6 +/- 3.9%; 36.8 +/- 5.7 AU), but revealed a significantly higher percentage and intensity of p53 staining than the low-grade dysplasia (n = 14, 25.6 +/- 3.3%; 12.2 +/- 2.0 AU) and benign group (n = 10, 10.0 +/- 3.3%; 5.8 +/- 1.7 AU). Percentage of p53-positive cells counted by ACIS was similar to that obtained by manual counting. In addition, expression of Ki-67 in all four groups paralleled p53 expression. The authors' data showing overexpression of p53 and Ki-67 in high-grade urothelial dysplasia/CIS similar to that observed in TCC support the notion that high-grade urothelial dysplasia/CIS is a precursor of invasive TCC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12607601     DOI: 10.1097/00129039-200212000-00007

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  7 in total

1.  Diagnosis of urothelial carcinoma in situ using blue light cystoscopy and the utility of immunohistochemistry in blue light-positive lesions diagnosed as atypical.

Authors:  Filippo Pederzoli; Belkiss Murati Amador; Iryna Samarska; Kara A Lombardo; Max Kates; Trinity J Bivalacqua; Andres Matoso
Journal:  Hum Pathol       Date:  2019-05-06       Impact factor: 3.466

2.  Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays.

Authors:  Dennis A Faith; William B Isaacs; James D Morgan; Helen L Fedor; Jessica L Hicks; Leslie A Mangold; Patrick C Walsh; Alan W Partin; Elizabeth A Platz; Jun Luo; Angelo M De Marzo
Journal:  Prostate       Date:  2004-11-01       Impact factor: 4.104

3.  Dysplastic urothelial changes accompany empagliflozin administration in urinary bladder of experimental diabetes.

Authors:  Ahmed A M Abdel-Hamid; Alaa El-Din L Firgany
Journal:  Int J Exp Pathol       Date:  2020-02-10       Impact factor: 1.925

4.  p53 null phenotype is a "positive result" in urothelial carcinoma in situ.

Authors:  Ankur R Sangoi; Emily Chan; Eman Abdulfatah; Bradley A Stohr; Jane Nguyen; Kiril Trpkov; Farshid Siadat; Michelle Hirsch; Sara Falzarano; Aaron M Udager; L Priya Kunju
Journal:  Mod Pathol       Date:  2022-03-23       Impact factor: 8.209

5.  Utility of a dual immunostain cocktail comprising of p53 and CK20 to aid in the diagnosis of non-neoplastic and neoplastic bladder biopsies.

Authors:  Isil Z Yildiz; Rosemary Recavarren; Henry B Armah; Sheldon Bastacky; Rajiv Dhir; Anil V Parwani
Journal:  Diagn Pathol       Date:  2009-10-14       Impact factor: 2.644

6.  Urothelial Carcinoma In Situ of the Bladder: Correlation of CK20 Expression With Adaptive Immune Resistance, Response to BCG Therapy, and Clinical Outcome.

Authors:  Kara A Lombardo; Belkiss Murati Amador; Vamsi Parimi; Jean Hoffman-Censits; Woonyoung Choi; Noah M Hahn; Max Kates; Trinity J Bivalacqua; David McConkey; Mohammad O Hoque; Andres Matoso
Journal:  Appl Immunohistochem Mol Morphol       Date:  2021-02-01

7.  Evaluation of a triple combination of cytokeratin 20, p53 and CD44 for improving detection of urothelial carcinoma in urine cytology specimens.

Authors:  Brent Arville; Emily O'Rourke; Fai Chung; Mahul Amin; Shikha Bose
Journal:  Cytojournal       Date:  2013-12-27       Impact factor: 2.091

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.